Immatics Presents Clinical Activity of IMA203CD8 PRAME Cell Therapy in Hard-to-Treat Gynecologic Cancers at 2026 ASCO Annual Meeting
Immatics N.V. presented updated Phase 1 clinical data at ASCO 2026 showing that their IMA203CD8 PRAME-directed TCR T-cell therapy achieved meaningful anti-tumor activity in heavily pretreated patients with platinum-resistant ovarian cancer, uterine cancer, and synovial sarcoma. The therapy demonstrated a 63% objective response rate in gynecologic c…